Minneapolis Clinical Trials
2037 Study (SAD)
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of single doses and multiple doses of an investigation drug that is being developed to treat sickle cell disease, in healthy participants.
11 nights
5 visits
During Study 2037, participants will receive the investigative treatment via a subcutaneous injection or an intravenous infusion.
There is one screening appointment and a COVID test before the overnight stay. There are five outpatient visits. Compensation for study participation may be provided for time and travel of $4,125.
This study has been approved by an independent ethics committee.
Call Andy at 651-332-1810 or email her at andyh@nucleusnetwork.com to discuss your eligibility today!
Eligibility
Biological Sex Healthy males or females (of non-child bearing potential)
Age 18 - 55 years old
BMI 17.5 - 30.5
Weight > 110 lbs
Smoking History Must be able to abstain from tobacco/nicotine use 24 prior to admission and throughout study